Eisai Co., Ltd. (ESALY)
Quick facts
| Ticker | ESALY (OTC) |
|---|
Marketed products
- Lenvima · Oncology · revenue 1053.0
Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells. - Aricept · Neuroscience · revenue 800
Aricept works by blocking the enzyme that breaks down a key neurotransmitter in the brain, acetylcholine. - Leqembi · Immunology · revenue 500
Leqembi works by binding to and removing amyloid beta A4 protein from the brain, which is thought to contribute to the progression of Alzheimer's disease. - Halaven · Oncology · revenue 400
Halaven works by binding to tubulin beta, disrupting microtubule dynamics and leading to cell death. - Hexalen · Oncology
- Ontak · Oncology
Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells. - E0671 · Other
- Ontak · Oncology
- HOPE · Other
- LEQEMBI · Neuroscience
- Dayvigo · Neuroscience
Dayvigo blocks the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles. - Belviq · Metabolic
- MENATETRANONE · Other
- Banzel · Neuroscience
Banzel works by stabilizing inactivated sodium channels in the brain, reducing the frequency of seizures.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: